Question explored with the scientific record
Tell me about the rsv snd pneumonia vaccines
The short version: RSV prevention tools work for severe disease in infants and older adults, but pneumococcal vaccines face serotype replacement that limits their long-term impact.
For RSV, the evidence is strongest for nirsevimab, a monoclonal antibody given to infants. In the HARMONIE trial, it cut RSV-related hospitalizations by about 83% [1]. A French study found it worked better than the maternal RSV vaccine (Abrysvo) for preventing infant hospital stays [1]. The maternal vaccine itself showed 82% efficacy against severe RSV in the first 90 days of life in the MATISSE trial [5]. But there is a real safety signal: a different maternal RSV vaccine from GSK was stopped early because of higher preterm birth rates (6.8% vs 4.9%) and a numerical imbalance in infant deaths [5]. For older adults, the RSV vaccines Arexvy and Abrysvo show around 82% efficacy against severe lower respiratory tract infection [6]. However, a large English safety study found about 23 extra cases of Guillain-Barré syndrome per million doses of the bivalent RSV vaccine in people aged 74-79 [7]. That is a small but real risk.
Pneumococcal vaccines have a different problem. The 7-valent and 13-valent conjugate vaccines clearly reduce disease from the serotypes they target. In Finland, PCV10 cut vaccine-type invasive disease by 92% [2]. But the bacteria adapt. In France, after PCV7 was introduced, non-vaccine serotype disease rose by 85% [3]. In England, serotypes 19A and 7F surged after PCV7 [4]. This serotype replacement means the overall benefit is smaller than the headline numbers suggest. For older adults, the CAPiTA trial showed PCV13 reduced vaccine-type pneumonia by 46% but did not significantly reduce all-cause pneumonia [9]. The 23-valent polysaccharide vaccine (PPSV23) is even weaker, with about 27% effectiveness against invasive disease in people over 65 [8].
| Intervention | Key benefit | Key limitation |
|---|---|---|
| Nirsevimab (infants) | 83% fewer RSV hospitalizations [1] | Resistance emerging in 12.5% of RSV-B breakthrough cases [1] |
| Maternal RSV vaccine (Abrysvo) | 82% efficacy severe RSV at 90 days [5] | GSK version linked to preterm birth [5] |
| RSV vaccine (older adults) | ~82% efficacy severe LRTI [6] | ~23 GBS cases per million doses [7] |
| PCV13 (children/adults) | 92% reduction vaccine-type IPD [2] | Non-vaccine serotypes rise 85% [3] |
| PPSV23 (older adults) | 27% VE against IPD [8] | No proven effect on pneumonia [10] |
My call: RSV monoclonal antibodies for infants have the strongest evidence for net benefit. RSV vaccines for older adults work but carry a small GBS risk worth knowing. Pneumococcal vaccines reduce targeted disease but serotype replacement means the net population benefit is modest and erodes over time. Confidence: moderate for RSV tools, low for long-term pneumococcal benefit.
Sources used 10
-
Nirsevimab for respiratory syncytial virus prevention: A comprehensive product review
Nirsevimab is a single-dose long-acting monoclonal antibody preventing RSV lower respiratory tract disease in infants, with high efficacy and effectiveness across trials and real-world programs, favorable safety, complementary use with maternal vaccination, and surveillance for …
DOI: 10.1080/21645515.2026.2726689 -
Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study
This population-based study evaluates the impact of the ten-valent pneumococcal conjugate vaccine (PCV10) on invasive pneumococcal disease (IPD) in Finnish children, demonstrating an 80% reduction in overall IPD rates among vaccinated children and significant indirect effects on…
DOI: 10.1371/journal.pone.0120290 -
Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006
In France, 7-valent pneumococcal conjugate vaccine introduction was followed by a 21% overall decrease in invasive pneumococcal disease in children under two years from 2001/2002 to 2006, driven by a 71% decrease in vaccine-type cases but partially offset by an 85% rise in non-v…
DOI: 10.2807/ese.13.35.18962-en -
Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England
Post-PCV7 introduction in North East England led to a 20% drop in overall invasive pneumococcal disease (IPD) with large reductions in PCV7 serotypes across all ages, accompanied by increases in non-PCV7 serotypes, illustrating serotype replacement and informing expectations for…
DOI: 10.1017/s0950268812000763 -
Maternal RSV vaccination to protect infants: current evidence and future directions
Maternal RSV vaccination with RSVpreF (Abrysvo) effectively protects infants against RSV-LRTI with an acceptable safety profile, while vaccine acceptance varies widely and implementation requires trust, cultural sensitivity, and equitable access.
DOI: 10.37349/eaa.2025.100988 -
Recent advances in the prevention and treatment of respiratory syncytial virus disease
A comprehensive up-to-date review of respiratory syncytial virus (RSV) prevention and treatment strategies, detailing licensed vaccines, maternal and pediatric options, long-acting monoclonal antibodies, and vaccines/treatments in development, with critical analysis of efficacy,…
DOI: 10.1099/jgv.0.002095 -
Assessing the risk of Guillain-Barré syndrome in older adults after bivalent RSV pre-F vaccination in England
A national vaccine-safety study in England found a small increased risk of Guillain-Barré syndrome after bivalent RSV pre-F vaccination in adults aged 74-79, with SCCS relative incidence 3.34 and about 23 attributable cases per million doses, outweighed by vaccine benefits.
DOI: 10.1038/s41467-025-66280-z -
Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality
Pediatric PCV vaccination programs create herd protection that reduces pneumococcal disease in seniors, while PPV23 shows variable protection in older adults and overall vaccination uptake remains suboptimal, highlighting the need for targeted nursing-home strategies and surveil…
DOI: 10.3390/geriatrics6010013 -
Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
PCV13 reduced vaccine-type pneumococcal CAP and invasive pneumococcal disease in older adults and had no serious adverse events, but did not significantly reduce all-cause CAP or non-vaccine-type CAP; the review concludes PCV13 is effective for vaccine-type disease.
DOI: 10.17294/2330-0698.1214 -
Community-acquired pneumonia and pneumococcal vaccination in the elderly
This narrative review describes the epidemiology, etiology, clinical features, and current Canadian recommendations for pneumococcal vaccination against community-acquired pneumonia in the elderly.
DOI: 10.5206/uwomj.v84i2.4296